Inhibrx Biosciences, Inc.

Inhibrx operates as a clinical-stage biopharmaceutical company focused on discovering and developing novel biologic therapeutic candidates. The company engineers these candidates using proprietary modular protein engineering platforms and single domain antibody technologies designed to address challenging biological targets. Its active clinical pipeline centers on two oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist evaluated for chondrosarcoma, Ewing sarcoma, and colorectal adenocarcinoma, and INBRX-106, a hexavalent OX40 agonist investigated for solid tumors such as non-small cell lung cancer and head and neck squamous cell carcinoma. Because its therapeutic candidates are currently in clinical development, the company has no approved commercial products and does not yet serve end customers.

The company conducts clinical research internationally, including a global clinical trial conducted across 68 sites worldwide. Its patent estate spans the United States along with international jurisdictions including Europe, Australia, Canada, China, and Japan. The provided text does not mention the location of the company's headquarters.

Summary of the business section of Inhibrx Biosciences's latest annual report, written by StockData.

“As of December 31, 2025, we had 110 employees, 109 of whom were full-time, 84 of whom were engaged in research and development activity, and 51 of which hold advanced degrees, including but not limited to Ph.D., M.D., PharmD, J.D., MBA, and other master’s degrees.”